{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:14:48Z","timestamp":1777680888964,"version":"3.51.4"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100010256","name":"Guangzhou Municipal Science and Technology Project","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010256","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004000","name":"Guangzhou Science and Technology Program Key Projects","doi-asserted-by":"publisher","award":["202102070001"],"award-info":[{"award-number":["202102070001"]}],"id":[{"id":"10.13039\/501100004000","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.bioorg.2026.109843","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T06:52:39Z","timestamp":1775544759000},"page":"109843","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Discovery of the first-in-class highly potent FXR\/HSD17B13 dual modulator for the treatment of metabolic dysfunction-associated steatohepatitis"],"prefix":"10.1016","volume":"176","author":[{"given":"Xue","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuxia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongcheng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhican","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenli","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiajing","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuanbin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guohua","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2026.109843_bb0005","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","year":"2024","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bioorg.2026.109843_bb0010","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/nrgastro.2013.183","article-title":"NAFLD, NASH and liver cancer","volume":"10","author":"Michelotti","year":"2013","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.bioorg.2026.109843_bb0015","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/med.21991","article-title":"FXR agonists for MASH therapy: lessons and perspectives from obeticholic acid","volume":"44","author":"Wang","year":"2024","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.bioorg.2026.109843_bb0020","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1016\/j.cmet.2021.06.012","article-title":"FXR activation protects against NAFLD via bile-acid-dependent reductions in lipid absorption","volume":"33","author":"Clifford","year":"2021","journal-title":"Cell Metab."},{"key":"10.1016\/j.bioorg.2026.109843_bb0025","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.tibs.2006.08.002","article-title":"FXR, a multipurpose nuclear receptor","volume":"31","author":"Lee","year":"2006","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.bioorg.2026.109843_bb0030","doi-asserted-by":"crossref","first-page":"9363","DOI":"10.1021\/acs.jmedchem.3c00456","article-title":"Discovery of HPG1860, a structurally novel nonbile acid FXR agonist currently in clinical development for the treatment of nonalcoholic steatohepatitis","volume":"66","author":"Mo","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109843_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114886","article-title":"Discovery and development of palmatine analogues as anti-NASH agents by activating farnesoid x receptor (FXR)","volume":"245","author":"Zhang","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109843_bb0040","doi-asserted-by":"crossref","first-page":"6082","DOI":"10.1021\/acs.jmedchem.2c01918","article-title":"Discovery of the first-in-class intestinal restricted FXR and FABP1 dual modulator ZLY28 for the treatment of nonalcoholic fatty liver disease","volume":"66","author":"Ren","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109843_bb0045","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1021\/jm0002127","article-title":"Identification of a chemical tool for the orphan nuclear receptor FXR","volume":"43","author":"Maloney","year":"2000","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109843_bb0050","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/hep.30509","article-title":"The nonsteroidal farnesoid x receptor agonist cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with primary sclerosing cholangitis","volume":"70","author":"Trauner","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.bioorg.2026.109843_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.117082","article-title":"Design, synthesis, and biological evaluation of novel highly potent FXR agonists bearing piperidine scaffold","volume":"282","author":"Wang","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109843_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115614","article-title":"Design, synthesis, and biological studies of novel sulfonamide derivatives as farnesoid x receptor agonists","volume":"258","author":"Wang","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109843_bb0065","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1002\/hep.30350","article-title":"17-Beta hydroxysteroid dehydrogenase 13 is a hepatic retinol dehydrogenase associated with histological features of nonalcoholic fatty liver disease","volume":"69","author":"Ma","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.bioorg.2026.109843_bb0070","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.mce.2018.10.014","article-title":"Role of HSD17B13 in the liver physiology and pathophysiology","volume":"489","author":"Su","year":"2019","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.bioorg.2026.109843_bb0075","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1056\/NEJMoa1712191","article-title":"A protein-truncating HSD17B13 variant and protection from chronic liver disease","volume":"378","author":"Abul-Husn","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioorg.2026.109843_bb0080","doi-asserted-by":"crossref","first-page":"11437","DOI":"10.1073\/pnas.1410741111","article-title":"Comparative proteomic study reveals 17\u03b2-HSD13 as a pathogenic protein in nonalcoholic fatty liver disease","volume":"111","author":"Su","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bioorg.2026.109843_bb0085","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2217543120","article-title":"Inhibition of HSD17B13 protects against liver fibrosis by inhibition of pyrimidine catabolism in nonalcoholic steatohepatitis","volume":"120","author":"Luukkonen","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bioorg.2026.109843_bb0090","first-page":"C880","article-title":"BI-3231, an enzymatic inhibitor of HSD17B13, reduces lipotoxic effects induced by palmitic acid in murine and human hepatocytes","volume":"326","author":"Alcober-Boquet","year":"2024","journal-title":"Am. J. Phys. Cell Phys."},{"key":"10.1016\/j.bioorg.2026.109843_bb0095","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1021\/acs.jmedchem.2c01884","article-title":"Discovery of a novel potent and selective HSD17B13 inhibitor, BI-3231, a well-characterized chemical probe available for open science","volume":"66","author":"Thamm","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109843_bb0100","doi-asserted-by":"crossref","first-page":"11127","DOI":"10.1021\/acs.jmedchem.5c00119","article-title":"Discovery of highly potent, selective, and liver-targeting HSD17B13 inhibitor with robust in vivo anti-MASH activity","volume":"68","author":"Chen","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109843_bb0105","doi-asserted-by":"crossref","first-page":"22938","DOI":"10.1021\/acs.jmedchem.5c01825","article-title":"Discovery of the first-in-class HSD17B13\/PPAR multitarget modulators for the treatment of metabolic dysfunction-associated steatohepatitis","volume":"68","author":"Liang","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109843_bb0110","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.jhep.2022.11.025","article-title":"A phase I\/II study of ARO-HSD, an RNA interference therapeutic, for the treatment of non-alcoholic steatohepatitis","volume":"78","author":"Mak","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bioorg.2026.109843_bb0115","doi-asserted-by":"crossref","first-page":"6127","DOI":"10.1021\/acs.jmedchem.4c02720","article-title":"Discovery of first-in-class FXR and HSD17B13 dual modulator for the treatment of metabolic dysfunction-associated fatty liver disease","volume":"68","author":"Jiao","year":"2025","journal-title":"J. Med. Chem."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826003792?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826003792?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:37:50Z","timestamp":1777451870000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826003792"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":23,"alternative-id":["S0045206826003792"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.109843","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of the first-in-class highly potent FXR\/HSD17B13 dual modulator for the treatment of metabolic dysfunction-associated steatohepatitis","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.109843","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109843"}}